Sign In
Buy FHTX
$4.53
-0.210 (-4.43%)
At Close: Jul 31, 2026
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
01:49pm, Thursday, 16'th Feb 2023
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
09:48am, Tuesday, 08'th Nov 2022
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
07:00am, Thursday, 20'th Oct 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics: Selling For Less Than Cash Value
05:27pm, Monday, 10'th Oct 2022
Today, we put Foghorn Therapeutics in the spotlight for the first time. The company is developing several early stage drug candidates, and the stock trades currently for less than the net cash on the
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
04:05pm, Thursday, 01'st Sep 2022
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases
Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold
12:47pm, Tuesday, 23'rd Aug 2022
Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
09:47am, Tuesday, 09'th Aug 2022
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -24.53% and 68.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the sto
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
08:00am, Monday, 01'st Aug 2022
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically det
Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
02:52pm, Thursday, 02'nd Jun 2022
Foghorn has partnering deals with major big pharma. They have a novel technology which no one else seems to have.
Foghorn Therapeutics Announces Upcoming Investor Conference Participation
04:05pm, Tuesday, 31'st May 2022
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically dete
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
06:38am, Friday, 20'th May 2022
The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ: FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myel
Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
08:00am, Friday, 01'st Apr 2022
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically de
Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?
09:02am, Wednesday, 23'rd Mar 2022
Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%
11:31am, Wednesday, 12'th Jan 2022
The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
